| Revision as of 10:19, 1 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or [[user ...← Previous edit | Latest revision as of 21:22, 10 January 2025 edit undoArthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix | ||
| (86 intermediate revisions by 56 users not shown) | |||
| Line 1: | Line 1: | ||
| {{short description|Opioid analgesic}} | |||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | | Verifiedfields = changed | ||
| | Watchedfields = changed | |||
| | verifiedrevid = |
| verifiedrevid = 464215177 | ||
| | IUPAC_name = (1,3- |
| IUPAC_name = (1,3-Dimethyl-4-phenylpiperidin-4-yl) propanoate | ||
| | image = Alphaprodine.svg | | image = Alphaprodine.svg | ||
| | image_class = skin-invert-image | |||
| | width = |
| width = 180 | ||
| | alt = Skeletal formula of prodine | |||
| | image2 = Prodine molecule ball.png | |||
| | width2 = 160 | |||
| | alt2 = Ball-and-stick model of the prodine molecule | |||
| <!--Clinical data--> | <!--Clinical data--> | ||
| Line 11: | Line 18: | ||
| | pregnancy_US = <!-- A / B / C / D / X --> | | pregnancy_US = <!-- A / B / C / D / X --> | ||
| | pregnancy_category = | | pregnancy_category = | ||
| | legal_AU = |
| legal_AU = S8 | ||
| | legal_BR = A1 | |||
| | legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=] |language=pt-BR |publication-date=2023-04-04}}</ref> | |||
| | legal_CA = <!-- Schedule I --> | | legal_CA = <!-- Schedule I --> | ||
| | legal_UK = <!-- Class A --> | | legal_UK = <!-- Class A --> | ||
| | legal_US = Schedule |
| legal_US = Schedule I | ||
| | |
| legal_DE = Anlage I | ||
| | legal_status = Rx-only | |||
| | routes_of_administration = |
| routes_of_administration = | ||
| <!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| Line 23: | Line 33: | ||
| | metabolism = | | metabolism = | ||
| | elimination_half-life = | | elimination_half-life = | ||
| | excretion = |
| excretion = | ||
| <!--Identifiers--> | <!--Identifiers--> | ||
| | CAS_supplemental = | |||
| | CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|correct|CAS}} (alpha) | ||
| | CAS_number = 77-20-3 | | CAS_number = 77-20-3 | ||
| | |
| CAS_number2_Ref = {{cascite|correct|CAS}} (beta) | ||
| | CAS_number2 = 468-59-7 | |||
| | ATC_prefix = none | | ATC_prefix = none | ||
| | ATC_suffix = | | ATC_suffix = | ||
| Line 38: | Line 50: | ||
| | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| | ChemSpiderID = 176845 | | ChemSpiderID = 176845 | ||
| | UNII_Ref = {{fdacite|changed|FDA}} | |||
| | UNII = 001O2254AC | |||
| | UNII2_Ref = {{fdacite|correct|FDA}} | |||
| | UNII2 = 21J54X4Z4Z | |||
| | KEGG_Ref = {{keggcite|correct|kegg}} | |||
| | KEGG = D12678 | |||
| | KEGG2_Ref = {{keggcite|correct|kegg}} | |||
| | KEGG2 = D12679 | |||
| <!--Chemical data--> | <!--Chemical data--> | ||
| | C=16 | H=23 | N=1 | O=2 | | C=16 | H=23 | N=1 | O=2 | ||
| ⚫ | | smiles = O=C(CC)O1(CCN(C1C)C)C2=CC=CC=C2 | ||
| | molecular_weight = 261.359 g/mol | |||
| ⚫ | | smiles = O=C(O |
||
| | InChI = 1/C16H23NO2/c1-4-15(18)19-16(14-8-6-5-7-9-14)10-11-17(3)12-13(16)2/h5-9,13H,4,10-12H2,1-3H3/t13-,16+/m1/s1 | |||
| | InChIKey = UVAZQQHAVMNMHE-CJNGLKHVBH | |||
| | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | StdInChI = 1S/C16H23NO2/c1-4-15(18)19-16(14-8-6-5-7-9-14)10-11-17(3)12-13(16)2/h5-9,13H,4,10-12H2,1-3H3/t13-,16+/m1/s1 | | StdInChI = 1S/C16H23NO2/c1-4-15(18)19-16(14-8-6-5-7-9-14)10-11-17(3)12-13(16)2/h5-9,13H,4,10-12H2,1-3H3/t13-,16+/m1/s1 | ||
| Line 52: | Line 70: | ||
| }} | }} | ||
| '''Prodine''' (trade names '''Prisilidine''' and '''Nisentil''') is an ] ] that is an ] of ] (meperidine). | '''Prodine'''<ref>US Patent 2498433 '1,3 dimethyl-4-propionoxy-4-phenyl-piperidine and acid addition salts thereof'</ref> (trade names '''Prisilidine''' and '''Nisentil''') is an ] ] that is an ] of ] (meperidine). It was developed in Germany in the late 1940s. | ||
| There are two ]s of prodine, |
There are two ]s of the trans form of prodine, alphaprodine and betaprodine. Both exhibit optical isomerism and alphaprodine and betaprodine are ]s.<ref name=Reynolds>{{Cite book | vauthors = Reynolds AK, Randall LO | title = Morphine & Allied Drugs | date = 1957 | pages = 310–312 | publisher = University of Toronto Press | oclc = 1628783 }}</ref> Alphaprodine is closely related to ] in steric configuration.<ref name=Reynolds/> The cis form also has active isomers but none are used in medicine.<ref name=Reynolds/><ref>{{cite journal |vauthors=Beckett AH, Walker J | title = The configuration of alphaprodine and betaprodine | journal = Journal of Pharmacy and Pharmacology | year = 1955 | volume = 7 | issue = 1 | pages = 1039–1045 | doi = 10.1111/j.2042-7158.1955.tb12115.x | pmid = 13278850| s2cid = 46012276 }}</ref> Betaprodine is around five times more potent than alphaprodine<ref>{{cite book | vauthors = Stenlake JB | title = Foundations of Molecular Pharmacology | year = 1979 | isbn = 978-0-485-11171-2}}</ref> but is metabolized more rapidly, and only alphaprodine was developed for medicinal use. It has similar activity to pethidine, but with a more rapid onset and shorter duration of effects.<ref>{{cite journal |vauthors=Fung DL, Asling JH, Eisele JH, Martucci R | title = A comparison of alphaprodine and meperidine pharmacokinetics | journal = Journal of Clinical Pharmacology | year = 1980 | volume = 20 | issue = 1 | pages = 37–41 | doi = 10.1002/j.1552-4604.1980.tb01664.x | pmid = 7358866| s2cid = 35046059 }}</ref> Betaprodine produces more ] and side effects than alphaprodine at all dose levels, and it was found that 5 to 10 mg of betaprodine is equivalent to 25 to 40 mg of alphaprodine.<ref name=Reynolds/> | ||
| Testing in rats showed alphaprodine to be 97% the strength of ] via the ] route and 140% the strength of oral ].<ref name=Reynolds/> Betaprodine was 550% stronger than morphine SC, the ] cis isomer was 350% stronger, and the ] cis isomer was 790% stronger.<ref name=Reynolds/> Betaprodine taken orally was 420% stronger than oral methadone, the cis form was 390% stronger for the laevorotatory and 505% stronger for the dextrorotatory isomers.<ref name=Reynolds/> | |||
| ] | |||
| ] | |||
| ⚫ | Alphaprodine was sold under several brand names, mainly Nisentil and Prisilidine. It was |
||
| ⚫ | Alphaprodine was sold under several brand names, mainly Nisentil and Prisilidine. It was most commonly used for pain relief during ]<ref>{{cite journal |vauthors=Burnett RG, White CA | title = Alphaprodine for continuous intravenous obstetric analgesia | journal = Obstetrics & Gynecology | year = 1966 | volume = 27 | issue = 4 | pages = 472–477 | doi = 10.1097/00006250-196604000-00003| pmid = 5907367 }}</ref> and ],<ref>{{cite journal |vauthors=Carter WJ, Bogert JA | title = An effective pre-medication procedure for dental patients | journal = Journal of the Missouri Dental Association | year = 1966 | volume = 46 | issue = 6 | pages = 8–9 | pmid = 5221807}}</ref> as well as for some minor surgical procedures. Alphaprodine has a duration of action of 1 to 2 hours, and 40 to 60 mg is equivalent to 10 mg of subcutaneous morphine. | ||
| ⚫ | Prodine has similar effects to other opioids, |
||
| ⚫ | Prodine has broadly similar effects to other opioids, producing ], ] and euphoria. Side effects can include excessive ], ], ] and potentially serious ] which can lead to life-threatening ]. Respiratory depression can be a problem with alphaprodine even at normal therapeutic doses.<ref>{{cite journal |vauthors=Fuller JD, Crombleholme WR | title = Respiratory arrest and prolonged respiratory depression after one low, subcutaneous dose of alphaprodine for obstetric analgesia. A case report | journal = Journal of Reproductive Medicine | year = 1987 | volume = 32 | issue = 2 | pages = 149–151 | pmid = 3560080}}</ref> Unlike pethidine, prodine does not produce toxic metabolites and is therefore more suitable for high-dose therapy.{{medcn|date=September 2013}} | ||
| ⚫ | == References == | ||
| <references /> | |||
| ==Regulation== | |||
| {{opioids}} | |||
| Alphaprodine has a DEA ACSCN of 9010 and 2013 manufacturing quota of 3 grams; betaprodine has an ACSCN of 9611 and a 2 grams quota. | |||
| ==See also== | |||
| ⚫ | ] | ||
| * ] | |||
| ⚫ | ] | ||
| * ] | |||
| ] | |||
| ⚫ | ] | ||
| ⚫ | == References == | ||
| {{Reflist|2}} | |||
| {{ |
{{Opioidergics}} | ||
| ⚫ | ] | ||
| ] | |||
| ] | ] | ||
| ⚫ | ] | ||
| ⚫ | ] | ||
Latest revision as of 21:22, 10 January 2025
Opioid analgesic Pharmaceutical compound | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H23NO2 |
| Molar mass | 261.365 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Prodine (trade names Prisilidine and Nisentil) is an opioid analgesic that is an analog of pethidine (meperidine). It was developed in Germany in the late 1940s.
There are two isomers of the trans form of prodine, alphaprodine and betaprodine. Both exhibit optical isomerism and alphaprodine and betaprodine are racemates. Alphaprodine is closely related to desomorphine in steric configuration. The cis form also has active isomers but none are used in medicine. Betaprodine is around five times more potent than alphaprodine but is metabolized more rapidly, and only alphaprodine was developed for medicinal use. It has similar activity to pethidine, but with a more rapid onset and shorter duration of effects. Betaprodine produces more euphoria and side effects than alphaprodine at all dose levels, and it was found that 5 to 10 mg of betaprodine is equivalent to 25 to 40 mg of alphaprodine.
Testing in rats showed alphaprodine to be 97% the strength of morphine via the subcutaneous route and 140% the strength of oral methadone. Betaprodine was 550% stronger than morphine SC, the laevorotatory cis isomer was 350% stronger, and the dextrorotatory cis isomer was 790% stronger. Betaprodine taken orally was 420% stronger than oral methadone, the cis form was 390% stronger for the laevorotatory and 505% stronger for the dextrorotatory isomers.
Alphaprodine was sold under several brand names, mainly Nisentil and Prisilidine. It was most commonly used for pain relief during childbirth and dentistry, as well as for some minor surgical procedures. Alphaprodine has a duration of action of 1 to 2 hours, and 40 to 60 mg is equivalent to 10 mg of subcutaneous morphine.
Prodine has broadly similar effects to other opioids, producing analgesia, sedation and euphoria. Side effects can include excessive itching, nausea, vomiting and potentially serious respiratory depression which can lead to life-threatening respiratory arrest. Respiratory depression can be a problem with alphaprodine even at normal therapeutic doses. Unlike pethidine, prodine does not produce toxic metabolites and is therefore more suitable for high-dose therapy.
Regulation
Alphaprodine has a DEA ACSCN of 9010 and 2013 manufacturing quota of 3 grams; betaprodine has an ACSCN of 9611 and a 2 grams quota.
See also
References
- Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- US Patent 2498433 '1,3 dimethyl-4-propionoxy-4-phenyl-piperidine and acid addition salts thereof'
- ^ Reynolds AK, Randall LO (1957). Morphine & Allied Drugs. University of Toronto Press. pp. 310–312. OCLC 1628783.
- Beckett AH, Walker J (1955). "The configuration of alphaprodine and betaprodine". Journal of Pharmacy and Pharmacology. 7 (1): 1039–1045. doi:10.1111/j.2042-7158.1955.tb12115.x. PMID 13278850. S2CID 46012276.
- Stenlake JB (1979). Foundations of Molecular Pharmacology. ISBN 978-0-485-11171-2.
- Fung DL, Asling JH, Eisele JH, Martucci R (1980). "A comparison of alphaprodine and meperidine pharmacokinetics". Journal of Clinical Pharmacology. 20 (1): 37–41. doi:10.1002/j.1552-4604.1980.tb01664.x. PMID 7358866. S2CID 35046059.
- Burnett RG, White CA (1966). "Alphaprodine for continuous intravenous obstetric analgesia". Obstetrics & Gynecology. 27 (4): 472–477. doi:10.1097/00006250-196604000-00003. PMID 5907367.
- Carter WJ, Bogert JA (1966). "An effective pre-medication procedure for dental patients". Journal of the Missouri Dental Association. 46 (6): 8–9. PMID 5221807.
- Fuller JD, Crombleholme WR (1987). "Respiratory arrest and prolonged respiratory depression after one low, subcutaneous dose of alphaprodine for obstetric analgesia. A case report". Journal of Reproductive Medicine. 32 (2): 149–151. PMID 3560080.